4/17/2024
Small Biotech Cullinan Goes All-In on Autoimmune CAR-T in $280M Pivot
In a bold strategic move, small-cap biotech Cullinan Oncology is transforming into an autoimmune disease company and rebranding as Cullinan Therapeutics. The Massachusetts company announced the major pivot alongside a $280 million private placement financing that extends its cash runway into 2028.
0
3 min read